Javascript must be enabled to continue!
Drug-coated balloon-first versus drug-eluting stent strategy for de novo diffuse left anterior descending disease: a propensity-weighted cohort
View through CrossRef
Abstract
Background
Diffuse left anterior descending coronary disease often forces long, overlapping stent segments. That solves acute scaffolding but leaves a large permanent metal footprint, which can translate into repeat revascularisation in real-world follow-up. A drug-coated balloon-first approach aims to deliver antiproliferative therapy without an implant, but the practical concern is whether balloon-only treatment can achieve a reliable final result in long lesions and whether any short-term advantage persists beyond the procedure.
Purpose
To compare a drug-coated balloon-first strategy (bail-out stenting permitted) with a drug-eluting stent strategy for procedural success and 12-month clinical outcomes in de novo diffuse left anterior descending disease.
Methods
We analysed consecutive adults undergoing percutaneous coronary intervention between January 2023 and December 2024 for de novo left anterior descending lesions with angiographic length ≥20 mm. In-stent restenosis and planned hybrid index strategies were excluded to keep treatment attribution clear. Because operators tend to select drug-coated balloons for different anatomy than stents, we chose inverse probability of treatment weighting to reduce confounding while preserving the full cohort, and we checked overlap and balance after weighting. Time-to-event outcomes were assessed using Kaplan–Meier methods and Cox regression; a prespecified strategy-based sensitivity analysis retained bail-out conversions within the attempted drug-coated balloon group.
Results
Among 520 patients, 262 underwent a drug-coated balloon-first strategy and 258 underwent a drug-eluting stent strategy. Lesion complexity was higher in the drug-coated balloon group (type C: 181/262 [69.1%] vs 145/258 [56.2%]). Procedural success was similar (255/262 [97.3%] vs 248/258 [96.1%]). At 12 months, major adverse cardiovascular events occurred less often with the drug-coated balloon strategy (28/262 [10.7%] vs 43/258 [16.7%]), driven by fewer target lesion revascularisations (12/262 [4.6%] vs 27/258 [10.5%]). Event-free survival was higher with drug-coated balloon-first (hazard ratio for drug-eluting stent vs drug-coated balloon 2.01, 95% confidence interval 1.21–3.42; Cox p=0.008). Here’s the trade-off: these differences are clinically meaningful in a long-lesion setting, but residual confounding remains possible despite weighting and prespecified sensitivity analyses.
Conclusion
In de novo diffuse left anterior descending disease, a drug-coated balloon-first strategy achieved comparable procedural success and was associated with lower 12-month major adverse cardiovascular events and repeat revascularisation than drug-eluting stenting. These real-world data support a "leave-nothing-behind" option in selected long lesions, while randomised trials with protocolised angiographic follow-up are needed to confirm durability and clarify which anatomical subsets benefit most.Adjusted cox model for time to mACE.For image description, please refer to the figure legend and surrounding text.MACE-free survival and propensity scoreFor image description, please refer to the figure legend and surrounding text.
Oxford University Press (OUP)
Title: Drug-coated balloon-first versus drug-eluting stent strategy for de novo diffuse left anterior descending disease: a propensity-weighted cohort
Description:
Abstract
Background
Diffuse left anterior descending coronary disease often forces long, overlapping stent segments.
That solves acute scaffolding but leaves a large permanent metal footprint, which can translate into repeat revascularisation in real-world follow-up.
A drug-coated balloon-first approach aims to deliver antiproliferative therapy without an implant, but the practical concern is whether balloon-only treatment can achieve a reliable final result in long lesions and whether any short-term advantage persists beyond the procedure.
Purpose
To compare a drug-coated balloon-first strategy (bail-out stenting permitted) with a drug-eluting stent strategy for procedural success and 12-month clinical outcomes in de novo diffuse left anterior descending disease.
Methods
We analysed consecutive adults undergoing percutaneous coronary intervention between January 2023 and December 2024 for de novo left anterior descending lesions with angiographic length ≥20 mm.
In-stent restenosis and planned hybrid index strategies were excluded to keep treatment attribution clear.
Because operators tend to select drug-coated balloons for different anatomy than stents, we chose inverse probability of treatment weighting to reduce confounding while preserving the full cohort, and we checked overlap and balance after weighting.
Time-to-event outcomes were assessed using Kaplan–Meier methods and Cox regression; a prespecified strategy-based sensitivity analysis retained bail-out conversions within the attempted drug-coated balloon group.
Results
Among 520 patients, 262 underwent a drug-coated balloon-first strategy and 258 underwent a drug-eluting stent strategy.
Lesion complexity was higher in the drug-coated balloon group (type C: 181/262 [69.
1%] vs 145/258 [56.
2%]).
Procedural success was similar (255/262 [97.
3%] vs 248/258 [96.
1%]).
At 12 months, major adverse cardiovascular events occurred less often with the drug-coated balloon strategy (28/262 [10.
7%] vs 43/258 [16.
7%]), driven by fewer target lesion revascularisations (12/262 [4.
6%] vs 27/258 [10.
5%]).
Event-free survival was higher with drug-coated balloon-first (hazard ratio for drug-eluting stent vs drug-coated balloon 2.
01, 95% confidence interval 1.
21–3.
42; Cox p=0.
008).
Here’s the trade-off: these differences are clinically meaningful in a long-lesion setting, but residual confounding remains possible despite weighting and prespecified sensitivity analyses.
Conclusion
In de novo diffuse left anterior descending disease, a drug-coated balloon-first strategy achieved comparable procedural success and was associated with lower 12-month major adverse cardiovascular events and repeat revascularisation than drug-eluting stenting.
These real-world data support a "leave-nothing-behind" option in selected long lesions, while randomised trials with protocolised angiographic follow-up are needed to confirm durability and clarify which anatomical subsets benefit most.
Adjusted cox model for time to mACE.
For image description, please refer to the figure legend and surrounding text.
MACE-free survival and propensity scoreFor image description, please refer to the figure legend and surrounding text.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract
Introduction
Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Two hundred forty-six patients with 252 bifurcation lesions were enrolled into a prospective, nonrandomized study to use paclitaxel-eluting or sirolimus-eluting stent for crush ste...
Predictors of insistent restenosis in patients undergoing percutaneous intervention
Predictors of insistent restenosis in patients undergoing percutaneous intervention
Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. The first percutaneous coronary intervention was performed by Andreas Gruntzig on Septemb...
Clinical study of biodegradable polymer stent versus durable polymer stent in treating long coronary lesions
Clinical study of biodegradable polymer stent versus durable polymer stent in treating long coronary lesions
Objective
This study compared the clinical efficacy and safety of homemade biodegradable polymer rapamycin-eluting stent (EXCEL TM) and durable polymer rapamycin-...
CLINICAL APPLICATION OF DOMESTIC LONG BIODEGRADABLE POLYMER COATED SIROLIMUS ELUTING STENTS FOR TREATMENT OF LONG CORONARY ARTERY LESIONS
CLINICAL APPLICATION OF DOMESTIC LONG BIODEGRADABLE POLYMER COATED SIROLIMUS ELUTING STENTS FOR TREATMENT OF LONG CORONARY ARTERY LESIONS
Objectives
To evaluate the efficacy and safety of domestic long biodegradable polymer coated sirolimus eluting stents (Excel stent, Shandong JW) for treatment of ...
Effects of PIP targeting LOX-1 eluting stents on in-stent restenosis and re-endothelialisation in rat abdominal aorta stenting models
Effects of PIP targeting LOX-1 eluting stents on in-stent restenosis and re-endothelialisation in rat abdominal aorta stenting models
Background and Objectives
Pyrrole-Imidazole polyamide (PIP) is a novel gene silencer that can be readily designed and synthesised to target any gene. Contrary to ...
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
BACKGROUND:
Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbrevi...

